Angiodynamics Inc
ANGO- Exchange
- Nasdaq
- Industry
- Surgical & Medical Instruments & Apparatus
- SEC CIK
- 0001275187
In the last 90 days, Angiodynamics Inc insiders filed 0 open-market purchases and 1 sale; 161 institutions reported holding it in 13F filings for Q2 2026, worth $492.8M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Angiodynamics Inc insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 1 filing
- 1 insider, $344.0K in total
- Insiders trading
- 1
- Net value
- −$344.0K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Angiodynamics Inc, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Nighan Warren JR | SVP Quality and Regulatory | 64,745 | Jul 31, 2026 | 4 |
| Piccinini Laura | SVP International | 81,929 | Jul 24, 2026 | 3 |
| Trowbridge Stephen A | EVP and CFO | 305,796 | Jul 24, 2026 | 4 |
| Clemmer James C | President and CEO | 862,448 | Jul 24, 2026 | 3 |
| Campbell Chad Thomas | SVP/GM, Vascular Access | 108,676 | Jul 24, 2026 | 3 |
| Reed Jan Stern | Director | 116,921 | Jul 22, 2026 | 1 |
| Licitra Karen A | Director | 102,322 | Jul 22, 2026 | 1 |
| Johnson Wesley | Director | 155,425 | Jul 22, 2026 | 1 |
| Donnelly Howard W | Director | 178,938 | Jul 22, 2026 | 1 |
| Burgess Lorinda | Director | 67,144 | Jul 22, 2026 | 1 |
| Auen Eileen O'Shea | Director | 116,605 | Jul 22, 2026 | 1 |
| Tarnoff Michael E | Director | 95,265 | Jul 22, 2026 | 1 |
| Weiss Lawrence T | SVP, Chief Legal Officer | 112,618 | Jul 22, 2026 | 3 |
| Helsel Dave | SVP Global Operations and R&D | 34,462 | Sep 21, 2023 | 0 |
| Centea Scott | SVP/GM, VIT | 62,951 | Sep 21, 2023 | 0 |
| Meteny Dennis S | Director | 140,019 | Jul 21, 2023 | 0 |
| Rosenzweig Richard C | SVP and General Counsel | 15,730 | Feb 7, 2023 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 31, 2026 (view filing)4:45 PM ET | Jul 30 | 1 day | Nighan Warren JRSVP Quality and Regulatory | SSale | −23.4K | $14.72 | −$344.0K | −26.5%64.7K after | |
| Oct 22, 2025 (view filing) | Oct 21 | 1 day | Weiss Lawrence TSVP, Chief Legal Officer | PPurchase | +10.0K | $11.81 | +$118.1K | +12.0%93.6K after | |
| Oct 14, 2025 (view filing) | Oct 13 | 1 day | Trowbridge Stephen AEVP and CFO | PPurchase | +890 | $11.16 | +$9.93K | +0.3%256.6K after | |
| Oct 9, 2025 (view filing) | Oct 9 | Same day | Clemmer James CPresident and CEO | PPurchase | +10.0K | $11.15 | +$111.5K | +1.1%882.5K after | |
| Jan 17, 2025 (view filing) | Jan 16 | 1 day | Nighan Warren JRSVP Quality and Regulatory | SSale | −4.06K | $12.31 | −$50.0K | −8.8%41.8K after | |
| Oct 10, 2024 (view filing) | Oct 7-10 | 3 daysLate | Nighan Warren JRSVP Quality and Regulatory | PPurchase | +868 | $6.09 | +$5.29K | +1.9%45.9K after | 2 lots |
| Oct 8, 2024 (view filing) | Oct 8 | Same day | Trowbridge Stephen AEVP and CFO | PPurchase | +1.70K | $5.86 | +$9.96K | +1.0%172.7K after | |
| Oct 8, 2024 (view filing) | Oct 7 | 1 day | Clemmer James CPresident and CEO | PPurchase | +20.0K | $6.03 | +$120.6K | +3.0%681.6K after | 10b5-1 |
| Apr 8, 2024 (view filing) | Apr 8 | Same day | Clemmer James CPresident and CEO | PPurchase | +10.0K | $6.70 | +$67.0K | +1.9%539.1K after | |
| Feb 1, 2023 (view filing) | Jan 31 | 1 day | Helsel DaveSVP Global Operations and R&D | SSale | −4.63K | $12.95 | −$60.0K | −19.4%19.2K after | |
| Oct 12, 2022 (view filing) | Oct 12 | Same day | Trowbridge Stephen AEVP and CFO | PPurchase | +1.08K | $13.82 | +$15.0K | +1.2%89.6K after | |
| Oct 11, 2022 (view filing) | Oct 10 | 1 day | Clemmer James CPresident and CEO | PPurchase | +10.0K | $15.00 | +$150.0K | +2.3%450.4K after | |
| Aug 1, 2022 (view filing) | Jul 29 | 3 days | Helsel DaveSVP Global Operations and R&D | SSale | −5.00K | $22.44 | −$112.2K | −17.3%23.8K after | |
| May 2, 2022 (view filing) | Apr 28 | 4 days | Helsel DaveSVP Global Operations and R&D | SSale | −3.51K | $22.44 | −$78.8K | −13.3%22.9K after | |
| Apr 13, 2022 (view filing) | Apr 11-12 | 2 days | Johnson WesleyDirector | SSale | −7.50K | $23.05 | −$172.8K | −8.6%79.7K after | 2 lots |
| Jan 12, 2022 (view filing) | Jan 12 | Same day | Trowbridge Stephen AEVP and CFO | PPurchase | +1.00K | $22.64 | +$22.6K | +1.3%76.1K after | |
| Jan 12, 2022 (view filing) | Jan 11 | 1 day | Clemmer James CPresident and CEO | PPurchase | +10.0K | $22.84 | +$228.4K | +2.6%390.8K after | |
| Oct 21, 2021 (view filing) | Oct 20 | 1 day | Helsel DaveSVP Global Operations and R&D | SSale | −3.49K | $27.97 | −$97.7K | −11.7%26.4K after | |
| Oct 18, 2021 (view filing) | Oct 15 | 3 days | Centea ScottSr. VP/GM, Global VIT | SSale | −12.0K | $27.92 | −$335.0K | −20.6%46.2K after | |
| Oct 6, 2021 (view filing) | Oct 5 | 1 day | Campbell Chad ThomasSVP/GM, Vascular Access | SSale | −10.7K | $27.15 | −$291.8K | −25.3%31.7K after |